Pharmaceutical Technology's In the Lab eNewsletter
Enhanced sensitivity and ultra-high detection speed provide improved robustness and operability.
Shimadzu has released the LCMS-8060NX triple quadrupole mass spectrometer, which offers enhanced method development and routine analysis. A combination of high sensitivity and high detection speeds further improves ease-of-use and robustness. The system offers greater operating efficiency to pharmaceutical companies needing to shorten drug discovery periods or reduce costs, clinical firms that handle complex biological samples, and entities in food science involved in investigating residual pesticides, among others, the company announced in a June 9, 2020 press release.
In general, liquid chromatography–mass spectrometry (LC–MS) solutions provide the high selectivity, reliability, productivity, and sensitivity required in many industries. In particular, the new LCMS-8060NX enhances all these features and further strengthens Shimadzu's triple-quadrupole MS capabilities:
Source: Shimadzu
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.